GlassScriptPhysician profile
Candice Stewart Drewry
NPI 1952699530
$11,204.10
in general payments reported to CMS, 2019-2025
46 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $1,071 · 2021: $1,890 · 2022: $1,923 · 2023: $1,683 · 2024: $1,556 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,567.25 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,622.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,458.13 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,007.94 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $823.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $774.95 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $758.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $545.24 | 2019-2022 | |
| Lilly USA, LLC | $400.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.06 | 2019-2025 | Xifaxan |
| Allergan, INC. | $307.74 | 2019-2020 | |
| Amarin Pharma, INC. | $296.82 | 2020-2023 | |
| Astellas Pharma US INC | $251.52 | 2019-2025 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $221.83 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $194.84 | 2019-2022 | |
| Dexcom, INC. | $194.44 | 2021-2025 | Dexcom G6 Transmitter |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Drewry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.